Neuroimmunology

2019 ◽  
Keyword(s):  
Neurological Disorders ◽  
Clinical Presentation ◽  
Diagnostic Testing ◽  
Mechanisms Of Action ◽  
Diverse Group ◽  
Neuromyelitis Optica Spectrum Disorder ◽  
Inflammatory Myopathies ◽  
Immune Mediated ◽  
Adults And Children

This book provides clinical and supporting scientific background on a diverse group of neurological disorders in an expanding field of neurology, that of neuroimmunology. It includes chapters on multiple sclerosis and related disorders in adults and children, neuromyelitis optica spectrum disorder, Guillain-Barré syndrome, chronic inflammatory deymyelinating polyradiculoneuropathy and variants, immune-mediated disorders of the neuromuscular junction, inflammatory myopathies, paraneoplastic disorders and autoimmune encephalitities, and neurologic manifestations of systemic immune-mediated diseases. In addition there is an introductory chapter dealing with basic of immunology and another on mechanisms of action of therapies used in neuroimmunologic disorders. The clinical chapters cover epidemiology, pathology, pathogenesis, and pathophysiology of the different diseases along with clinical presentation, diagnostic testing, differential diagnosis, and treatment.

Paraneoplastic Neurological Disorders

2017 ◽  
Author(s):  
John C. Probasco
Keyword(s):  
Nervous System ◽  
Autonomic Nervous System ◽  
Diagnostic Test ◽  
Neurological Disorders ◽  
Clinical Presentation ◽  
Test Results ◽  
Patients With Cancer ◽  
Immune Mediated ◽  
Paraneoplastic Neurological Disorders ◽  
Symptoms And Signs

Paraneoplastic neurological disorders (PNDs) are estimated to affect approximately 0.01% of all patients with cancer. The majority of PNDs are thought to be the byproduct of immune-mediated processes directed against tumor-related antigens, processes which are sometimes effective against a systemic cancer. The inciting cancer is often asymptomatic or occult, with patients presenting to the neurologist with a variety of neurological symptoms and signs depending on the area(s) of the central, peripheral, and autonomic nervous system involved. The diagnosis of a PND is reserved for patients with histologically proven cancer; however, clinical presentation and diagnostic test results may make the diagnosis of a PND highly probable in the absence of the diagnosis of a cancer.

Biological therapy in idiopathic inflammatory myopathies

2014 ◽  
Vol 155 (1) ◽  
pp. 3-10
Author(s):  
Levente Bodoki ◽  
Melinda Nagy-Vincze ◽  
Zoltán Griger ◽  
Andrea Péter ◽  
Csilla András ◽  
...  
Keyword(s):  
T Cells ◽  
Muscle Weakness ◽  
Biological Therapy ◽  
Therapeutic Options ◽  
Idiopathic Inflammatory Myopathies ◽  
Inflammatory Myopathies ◽  
Progressive Muscle Weakness ◽  
Immune Mediated ◽  
Novel Therapeutic

Idiopathic inflammatory myopathies are systemic, immune-mediated diseases characterized by proximal, symmetrical, progressive muscle weakness. The aim of this work is to give an overview of the biological therapy used in the treatment of idiopathic inflammatory myopathies. The authors also focus on novel results in the therapy directed against the B- and T-cells. They emphasize the importance of new trials in these diseases which may lead to the introduction of novel therapeutic options in these disorders. Orv. Hetil., 2014, 155(1), 3–10.

Autophagy Modulators and Neuroinflammation

2020 ◽  
Vol 27 (6) ◽  
pp. 955-982 ◽  
Author(s):  
Kyoung Sang Cho ◽  
Jang Ho Lee ◽  
Jeiwon Cho ◽  
Guang-Ho Cha ◽  
Gyun Jee Song
Keyword(s):  
Neurodegenerative Disorders ◽  
Neurological Disorders ◽  
Mammalian Cells ◽  
Critical Role ◽  
Therapeutic Agents ◽  
Mechanisms Of Action ◽  
Scientific Interest ◽  
Therapeutic Tools ◽  
Underlying Mechanisms

Background: Neuroinflammation plays a critical role in the development and progression of various neurological disorders. Therefore, various studies have focused on the development of neuroinflammation inhibitors as potential therapeutic tools. Recently, the involvement of autophagy in the regulation of neuroinflammation has drawn substantial scientific interest, and a growing number of studies support the role of impaired autophagy in the pathogenesis of common neurodegenerative disorders. Objective: The purpose of this article is to review recent research on the role of autophagy in controlling neuroinflammation. We focus on studies employing both mammalian cells and animal models to evaluate the ability of different autophagic modulators to regulate neuroinflammation. Methods: We have mostly reviewed recent studies reporting anti-neuroinflammatory properties of autophagy. We also briefly discussed a few studies showing that autophagy modulators activate neuroinflammation in certain conditions. Results: Recent studies report neuroprotective as well as anti-neuroinflammatory effects of autophagic modulators. We discuss the possible underlying mechanisms of action of these drugs and their potential limitations as therapeutic agents against neurological disorders. Conclusion: Autophagy activators are promising compounds for the treatment of neurological disorders involving neuroinflammation.

Molecular Targets of Phytochemicals for Skin Inflammation

2018 ◽  
Vol 24 (14) ◽  
pp. 1533-1550 ◽  
Author(s):  
Jong-Eun Kim ◽  
Ki Won Lee
Keyword(s):  
Skin Diseases ◽  
Molecular Targets ◽  
Skin Inflammation ◽  
Mechanisms Of Action ◽  
The Body ◽  
Cellular Damage ◽  
Aesthetic Appearance ◽  
Immune Mediated ◽  
Skin Conditions ◽  
Effects Of Aging

Skin is a protective organ and the largest of the human body. Due to its pivotal role in aesthetic appearance, skin health has a significant impact on quality of life. Chronic inflammation of the skin often marks the beginning of various skin diseases. Immune-mediated responses serve to protect the body from external insults and require succinct control, and can lead to ongoing cellular damage and various skin conditions if left unchecked. Studies have shown that phytochemicals can alter processes involved in skin inflammation and alleviate the effects of aging, cancer, atopic dermatitis, psoriasis, and vitiligo. Direct molecular targets of some phytochemicals have been identified and their precise mechanisms of action investigated. In this review, we summarize recent findings on the effects of phytochemicals on skin inflammation and the mechanisms of action involved.

COVID-19 and neurology perspective

2021 ◽  
Vol 42 (1) ◽  
pp. 69-75
Author(s):  
Shivani Singh ◽  
Ashok Kumar Ahirwar ◽  
Priyanka Asia ◽  
Niranjan Gopal ◽  
Kirti Kaim ◽  
...  
Keyword(s):  
Neurological Disorders ◽  
Clinical Presentation ◽  
Sudden Onset ◽  
Natural Immunity ◽  
The Novel ◽  
Specific Antibodies ◽  
Initial Symptoms ◽  
Diet And Exercise ◽  
Short Span ◽  
Very High

Abstract COVID-19 caused by SARS CoV2 (The novel corona virus) has already taken lives of many people across the globe even more than anyone could have imagined. This outbreak occurred in China and since then it is expanding its devastating effects by leaps and bounds. Initially it appeared to be an outbreak of pneumonia but soon it was found to be much more than that and the infectivity was found to be very high. This is the reason that it has taken whole globe in its trap and become a pandemic in such a short span of time. Death is occurring because it is a new virus and human body has no specific antibodies for it. Presently there is no approved vaccine so everyone is susceptible but people with co-morbidities appear to be in more risk and the best way for protection is social distancing and increasing one’s natural immunity by taking healthy diet and exercise. When a person is infected the clinical presentation ranges from asymptomatic to severe ARDS, sudden onset of anosmia, headache, cough may be the initial symptoms. This review is focused on immunopathology and effect of COVID-19 on neurological disorders and also the neurological manifestations and the treatment.

scholarly journals The Hallmarks of Flavonoids in Cancer

Molecules ◽  
2021 ◽  
Vol 26 (7) ◽  
pp. 2029
Author(s):  
Luis Gustavo Saboia Ponte ◽  
Isadora Carolina Betim Pavan ◽  
Mariana Camargo Silva Mancini ◽  
Luiz Guilherme Salvino da Silva ◽  
Ana Paula Morelli ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cell Proliferation ◽  
Biological Activity ◽  
Neurological Disorders ◽  
Mechanisms Of Action ◽  
Molecular Signaling ◽  
Hallmarks Of Cancer ◽  
Redox Metabolism ◽  
Important Group ◽  
Cellular Context

Flavonoids represent an important group of bioactive compounds derived from plant-based foods and beverages with known biological activity in cells. From the modulation of inflammation to the inhibition of cell proliferation, flavonoids have been described as important therapeutic adjuvants against several diseases, including diabetes, arteriosclerosis, neurological disorders, and cancer. Cancer is a complex and multifactor disease that has been studied for years however, its prevention is still one of the best known and efficient factors impacting the epidemiology of the disease. In the molecular and cellular context, some of the mechanisms underlying the oncogenesis and the progression of the disease are understood, known as the hallmarks of cancer. In this text, we review important molecular signaling pathways, including inflammation, immunity, redox metabolism, cell growth, autophagy, apoptosis, and cell cycle, and analyze the known mechanisms of action of flavonoids in cancer. The current literature provides enough evidence supporting that flavonoids may be important adjuvants in cancer therapy, highlighting the importance of healthy and balanced diets to prevent the onset and progression of the disease.

scholarly journals Colistin neurotoxicity mimicking Guillain-Barré syndrome in a patient with cystic fibrosis: case report and review

2021 ◽  
Vol 2021 (9) ◽  
Author(s):  
Celeste Camargo ◽  
Tathagat Narula ◽  
Daniel A Jackson ◽  
Teresa Padro ◽  
W David Freeman
Keyword(s):  
Cystic Fibrosis ◽  
Drug Toxicity ◽  
Clinical Presentation ◽  
Guillain Barre Syndrome ◽  
Drug Induced ◽  
Common Presentation ◽  
Intravenous Treatment ◽  
Immune Mediated ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

ABSTRACT Guillain-Barré syndrome (GBS) is an immune-mediated polyneuropathy, which is characterized by areflexia and ascending paresthesia which can progress to a respiratory failure. Certain conditions, such as vasculitis and heavy metal and drug toxicity, may have misleadingly similar clinical presentation to GBS. We describe a case of a patient with cystic fibrosis and intravenous colistin-induced neurotoxicity mimicking GBS. The patient had used inhaled colistin on five occasions with no adverse effects, however, developed symptoms on the second day of intravenous treatment. Overlapping findings between immune-mediated polyneuropathy and drug-induced neurotoxicity include limb paresthesia and decreased reflexes. Perioral tingling, however, is a common presentation of colistin-induced neurotoxicity, and therefore, is an important differentiating factor. Early diagnosis prevents further neurologic decline, extensive unnecessary workup and potentially harmful incorrect management.

scholarly journals Inflammatory Pseudotumour of Stomach in an old lady: a rare case report

2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Azhar AH ◽  
Pasha MA ◽  
Hassan S ◽  
Zainal M ◽  
Rashidi A
Keyword(s):  
Case Report ◽  
Solid Tumor ◽  
Rare Case ◽  
Clinical Presentation ◽  
Inflammatory Pseudotumour ◽  
Secondary Neoplasms ◽  
Laboratory Techniques ◽  
Clinical Presentations ◽  
Rare Case Report ◽  
Adults And Children

Inflammatory pseudotumour (IPT) is a rare benign solid tumor in adults and children. The prevalence, etiology and pathogenesis of this condition are still uncertain. Despite the use of modern laboratory techniques and imaging, it is often difficult to make the diagnosis of IPT. Besides, occasionally the nonspecific morphological appearance and clinical presentation of the mass may mimic other more common primary or secondary neoplasms. IPT is commonly encountered in the lung and mediastinum. Other sites include abdomen (liver, pancreas, stomach, omentum), retroperitoneum, pelvis (bladder) and extremities in children. We report a rare case of gastric inflammatory pseudotumour in a 65-year-old female patient. Clinical presentations and its management along with review of literatures are presented.

Paediatric polymyositis and dermatomyositis

2013 ◽  
pp. 1021-1032
Author(s):  
Clarissa Pilkington ◽  
Liza McCann
Keyword(s):  
Controlled Trial ◽  
Collaborative Work ◽  
Assessment Tools ◽  
Inflammatory Myopathies ◽  
Double Blind ◽  
Drug Treatments ◽  
Adults And Children ◽  
Associated Malignancy ◽  
Subjective Study ◽  
Definition Of

Juvenile polymyositis and dermatomyositis are inflammatory myopathies that affect muscle. Dermatomyositis also affects skin, and can have many extramuscular manifestations. Inflammatory myopathies are uncommon in childhood, with dermatomyositis occurring more than polymyositis. For this reason, published research has concentrated on juvenile dermatomyositis. The spectrum of disease severity ranges from mild cases that can recover completely without treatment, to multisystem inflammation that can be fatal. Treatments have improved over the decades, reducing mortality from 30% before the era of steroids, to less than 1% in the present day. Juvenile cases of dermatomyositis differ from those seen in adulthood, without tendency for associated malignancy, and a far greater incidence of calcinosis. Calcinosis can be deposited as small calcinotic lumps or as sheets of calcinosis. It is very difficult to treat and causes extensive morbidity, and depending on where the calcinosis is deposited, it can cause severe disability or even death. Over the last decade, international collaborative work has concentrated on developing disease activity and assessment tools for both adult and juvenile forms of myositis. This will enable more subjective study of these rare diseases in multinational cohort studies, and enable clinical trials to investigate drug treatments. This work led to the first international double-blind placebo controlled trial of treatment in both adults and children with dermatomyositis (using rituximab as the drug). Further international collaboration has led to the development of core outcome variables, a definition of disease flare, and classification criteria.

Sign in / Sign up

Export Citation Format

Share Document